The failure of the phase 2 Moonsong outpatient trial prompts a phase 3 rethink and a one-year delay.
Astrazeneca’s Himalaya study is a surprising hit in first-line liver cancer, but competition is already present.
But a potentially more interesting advisory committee, for Merck and Ridgeback’s molnupiravir, awaits.
Turning Point and Repare are left nursing heavy losses, while Relay just about weathers a storm.
Two Xencor approaches with questions around them receive the backing of Johnson & Johnson.
Molnupiravir, a repurposed flu antiviral with a poor history, delivers in a pivotal study in Covid-19 outpatients.
Chemocentryx and Avadel will also see important FDA regulatory action this month, while Omeros gets another delay.